Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atovaquone + proguanil + artesunate + pyronaridine
- Development stage
- Preclinical
- Lead developer
- Wellcome Foundation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antimalarial therapy consisting of atovaquone, proguanil, artesunate, and pyronaridine. This combination incorporates components of artemisinin-based combination therapy (ACT) with atovaquone-proguanil. The combination has been studied for the treatment of uncomplicated Plasmodium falciparum malaria.
02
Targets
PfCYTB (Plasmodium falciparum cytochrome b)DHFR (Dihydrofolate reductase)Multiple Plasmodium falciparum targets involved in phospholipid metabolism and nucleic acid structures
Beyond the preview
Go deeper on atovaquone + proguanil + artesunate + pyronaridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atovaquone + proguanil + artesunate + pyronaridine.